Black Diamond Financial LLC Takes $3.83 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Black Diamond Financial LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 277,737 shares of the biotechnology company’s stock, valued at approximately $3,833,000. Black Diamond Financial LLC owned approximately 0.61% of Capricor Therapeutics at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. New York State Common Retirement Fund increased its holdings in Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 5,000 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in Capricor Therapeutics in the third quarter valued at $161,000. Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the third quarter valued at $192,000. SG Americas Securities LLC increased its holdings in Capricor Therapeutics by 74.8% in the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 6,552 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 15,872 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CAPR has been the topic of several research reports. Cantor Fitzgerald raised their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, January 2nd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Down 1.0 %

Shares of CAPR stock opened at $15.00 on Monday. The stock has a market capitalization of $682.05 million, a PE ratio of -14.15 and a beta of 4.08. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The stock’s 50-day moving average price is $14.24 and its 200 day moving average price is $13.41.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.